Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis
The use of GLP-1 RAs in patients with T2DM does not significantly increase the risk of gastric or esophageal cancer. This finding supports the continued use of GLP-1 analogues as a therapeutic option in managing T2DM, considering their well-established benefits and low risk of complications. Based on the study results, these medications may even have a protective effect against these malignancies.
Authors
- Muhammad Mujtaba Bhinder
- Tiana Dodd
- Muhammed Ceesay
- Nisar A. Amin
- Mark Ayoub (ORCID: https://orcid.org/0009-0002-6518-3971)
- Ebubekir Daglilar (ORCID: https://orcid.org/0000-0003-0622-1704)
- Rafi Aibani (ORCID: https://orcid.org/0000-0002-3222-9454)
- Carol Faris
Institutions
- West Virginia University (US)
- Charleston Area Medical Center (US)
- Bay Medical Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-09-22
- DOI
- https://doi.org/10.3390/cancers16183224
- Citations
- 11
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.93